210832-85-2

Basic information

• Product Name: 2-Bromo-1-(4-morpholinophenyl)-1-ethanone
• Synonyms: 2-BROMO-1-(4-MORPHOLINOPHENYL)-1-ETHANONE;BUTTPARK 146\50-45;2-Bromo-1-(4-morpholin-4-ylphenyl)ethanone;4-(Morpholin-4-yl)phenacyl bromide;4-(Morpholin-4-yl)phenacyl bromide 97%;2-Bromo-1-(4-morpholinophenyl)ethanone;2-Bromo-4'-morpholinoacetophenone;2-Bromo-4'-(morpholin-4-yl)acetophenone, 2-Bromo-1-[(4-morpholin-4-yl)phenyl]ethan-1-one
• CAS NO: 210832-85-2
• Molecular Formula: C₁₂H₁₄BrNO₂
• Molecular Weight: 284.15
• Product Categories: blocks;Bromides;pharmacetical;Acetyl Halides;Phenyls & Phenyl-Het;Acetyl Halides;Phenyls & Phenyl-Het
• Mol File: 210832-85-2.mol
• Article Data: 8

Chemical Properties

• Melting Point: 112 °C
• Boiling Point: 418.845 °C at 760 mmHg
• Flash Point: 207.111 °C
• Appearance: /
• Density: 1.439 g/cm³
• Vapor Pressure: 3.18E-07mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: Keep Cold
• Sensitive: Lachrymatory
• CAS DataBase Reference: 2-Bromo-1-(4-morpholinophenyl)-1-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-1-(4-morpholinophenyl)-1-ethanone(210832-85-2)
• EPA Substance Registry System: 2-Bromo-1-(4-morpholinophenyl)-1-ethanone(210832-85-2)

Safety Data

• Hazard Codes: C
• Statements: 36/37/38-34
• Safety Statements: 26-36/37/39-45
• Hazardous Substances Data: 210832-85-2(Hazardous Substances Data)

Usage

General Description

2-Bromo-1-(4-morpholinophenyl)-1-ethanone is a chemical compound with the molecular formula C10H12BrNO2. It is a brominated ketone with a morpholine ring and has a molecular weight of 260.11 g/mol. 2-Bromo-1-(4-morpholinophenyl)-1-ethanone is used in organic synthesis as a reagent or intermediate for the preparation of various pharmaceuticals and agrochemicals. It is also used as a building block for the synthesis of other organic compounds. The presence of the bromine and morpholine groups in its structure makes it a versatile compound with potential applications in the pharmaceutical and chemical industries. However, it is important to handle this compound carefully as it may have hazardous properties and should be used in a controlled environment by trained professionals.

InChI:InChI=1/C12H14BrNO2/c13-9-12(15)10-1-3-11(4-2-10)14-5-7-16-8-6-14/h1-4H,5-9H2

Upstream product

• 210832-82-9 2,2-Dibromo-1-(4-morpholin-4-yl-phenyl)-ethanone 
• 39910-98-0 4-morpholinoacetophenone 

Downstream Products

• 924899-53-6 2-(4-morpholinophenyl)-2-oxoethyl acetate 
• 1037828-58-2 4-[4-(1H-imidazol-4-yl)phenyl]morpholine 
• 1222343-69-2 C₁₉H₁₉N₃O₂S 
• 1415695-53-2 C₁₉H₁₈FN₃OS 
• 1601469-05-9 2-(2-(4-(4-morpholinophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid 
• 1601469-04-8 2-(2-(4-(4-morpholinophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid 

Relevant articles and documents

TGF-betaR1 inhibitor and application thereof

The invention belongs to the field of medical chemistry, and particularly relates to a compound serving as a TGF-betaR1 inhibitor and application of the compound. Specifically, the invention providesa compound shown as a formula I or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds or the composition to treatment and/or prevention of TGF-betaR1 related diseases, such as cancers, tissue hyperplasia diseases, fibrosis and inflammatory diseases. The compound provided by the invention shows significant inhibitory activity on TGF-betaR1 kinase, and is very expected to become a therapeutic agent for TGF-betaR1 related diseases.

Photo- and PH-switchable fluorescent diarylethenes based on 2,3-diarylcyclopent-2-en-1-ones with dialkylamino groups

New dialkylamino groups-comprising diarylethenes of 2,3-diarylcyclopent-2-en-1-one (DCP) series have been synthesized and its photochromic, fluorescent as well as acidochromic features have been investigated. It was shown that photochromic properties of t

Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: Clues for specific design of new compounds

Development of kinase-targeted therapies for central nervous system (CNS) diseases is a great challenge. Glycogen synthase kinase 3 (GSK-3) offers a great potential for severe CNS unmet diseases, being one of the inhibitors on clinical trials for different tauopathies. Following our hypothesis based on the enhanced reactivity of residue Cys199 in the binding site of GSK-3, we examine here the suitability of phenylhalomethylketones as irreversible inhibitors. Our data confirm that the halomethylketone unit is essential for the inhibitory activity. Moreover, addition of the halomethylketone moiety to reversible inhibitors turned them into irreversible inhibitors with IC50 values in the nanomolar range. Overall, the results point out that these compounds might be useful pharmacological tools to explore physiological and pathological processes related to signaling pathways regulated by GSK-3 opening new avenues for the discovery of novel GSK-3 inhibitors.